In Brief: LaserSight
This article was originally published in The Gray Sheet
Executive Summary
LaserSight: Acquires worldwide distribution rights to the Ruiz disposable microkeratome, an instrument used to create the corneal flap in laser in situ keratomileusis (LASIK) procedures, the St. Louis firm says. The company expects to begin international sales "late this year or early next year" at a price of approximately $7,500; a disposable component used with the device is priced at $125. A 510(k) will be submitted to FDA in the next few weeks for the device. Under the terms of the deal, LaserSight paid $400,000 in cash and supplied one LaserScan LSX scanning excimer laser to the instrument's inventors, Luis Antonio Ruiz, MD, and Sergio Lenchig of Bogota, Colombia; two additional payments of $150,000 each will be made six and 12 months after the initial shipment date...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.